Itraconazole amorphous solid dispersion tablets: formulation and compaction process optimization using Quality by Design principles and tools
first_published_at:Nov. 7, 2022, midnight / date_published:Nov. 7, 2022
Papers
-
07/11/2022 -
by
Hetvi Triboandas,
Kendal Pitt,
Mariana Bezerra,
Delphine Ach-Hubert,
Walkiria Schlindwein
BCS Class II drugs, exemplified by itraconazole (ITZ), are characterized by poor solubility (1–4 ng/mL), necessitating solubility enhancement. Consequently, amorphous solid dispersions (ASDs) of ITZ and Kollidon® VA64 (KOL) were …
